This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

Methotrexate in rheumatoid arthritis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Response to treatment cannot be expected before 2 months and may not occur until after 6 months treatment.

  • increasingly popular drug for this condition in the USA
  • once weekly dose
  • long term tolerability is better than that of gold, sulphasalazine, or penicillamine.
  • disease suppression starts earlier that with other slow-acting antirheumatics and patients are less likely to stop treatment
  • toxic effects include:
    • pneumonitis in 3% of patients
    • bone marrow suppression in approximately 3%
    • opportunistic infections
    • accelerated nodulosis of the hands
    • cirrhosis and liver failure - very rarely
  • overall side-effects are less common and can be minimised by folic acid supplementation

Reference:

  1. Porter DR. Medical management of rheumatoid arthritis. BMJ 1993; 307:425-428.
  2. Drug and Therapeutics Bulletin (1995). Methotrexate and rheumatoid arthritis. 33(3):17-19.
  3. Current Problems in Pharmacovigilance 2000; 26: 10.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.